GlassScriptPhysician profile
Nam H DO
NPI 1063456572
$8,315.71
in general payments reported to CMS, 2019-2025
37 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,527 · 2020: $294 · 2021: $11.86 · 2022: $135 · 2023: $1,006 · 2024: $2,422 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $999.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $861.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $768.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $698.57 | 2019-2025 | |
| Abbvie INC. | $626.32 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.62 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $586.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $540.89 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $419.02 | 2019-2025 | Otezla, Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $394.71 | 2019-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $294.82 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $238.33 | 2019-2025 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $221.36 | 2019-2025 | |
| Amarin Pharma, INC. | $188.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.86 | 2023-2025 | Xifaxan, Trulance |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $99.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $92.32 | 2019-2020 | |
| Dexcom, INC. | $56.63 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $53.04 | 2019-2023 | Belsomra, Steglatro, Segluromet |
| Lundbeck LLC | $38.22 | 2023 | Rexulti, Vyepti |
| Eisai INC. | $35.57 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $34.46 | 2019-2024 | Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $32.86 | 2025 | |
| Idorsia Pharmaceuticals US INC | $29.74 | 2023-2024 | Quviviq |
| Antares Pharma, INC. | $28.89 | 2019-2020 | |
| Exact Sciences Corporation | $27.95 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $26.32 | 2025 | Sunosi |
| Abbott Laboratories | $20.33 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $18.34 | 2024 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $15.68 | 2020 | |
| Viatris Specialty LLC | $15.35 | 2025 | Yupelri |
| Neurocrine Biosciences, INC. | $14.87 | 2023 | Ingrezza |
| Allergan, INC. | $14.54 | 2019 | |
| Genentech USA, INC. | $13.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.46 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nam DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.